Nestibil (Bilastine)

Bilastine, the active ingredient in Nestibil, is a second‑generation H1 antihistamine presented as an oral formulation for systemic use. It treats allergic rhinitis and chronic idiopathic urticaria in adult patients, providing relief from nasal congestion, itching, sneezing, and skin wheals.

GNH USA supplies Nestibil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Bilastine is indicated for conditions involving histamine‑mediated allergic responses.

Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhoea. Chronic idiopathic urticaria: alleviates wheals and pruritus. Hay fever: provides symptomatic relief of nasal and ocular allergy symptoms.

Bilastine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Dry mouth: transient sensation of oral dryness. - Fatigue: occasional tiredness without functional impairment. - Nausea: mild gastrointestinal upset. - Dizziness: brief episodes of light‑headedness. - Somnolence: rare, non‑sedating profile.

Serious or Rare Side Effects: - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Stevens‑Johnson syndrome: severe skin eruption. - Angioedema: swelling of face, lips or tongue. - Cardiac arrhythmia: rare conduction abnormalities. - Hepatic injury: elevated liver enzymes in isolated cases. - Severe hypersensitivity: rash, fever, eosinophilia.

Bilastine should be used with consideration of specific safety factors.

Pregnancy: consult a healthcare professional before use. Breastfeeding: weigh potential benefits against infant exposure. Renal impairment: monitor and adjust dose if necessary. Elderly: observe for increased sensitivity to central effects. Drug interactions: avoid concomitant strong CYP3A4 inhibitors. Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Bilastine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Ketoconazole: strong CYP3A4 inhibition may raise bilastine plasma levels. - Erythromycin: similar CYP3A4 inhibition risk. - Ritonavir: potent CYP3A4 inhibitor, can increase exposure.

Moderate Interactions (Monitor Closely): - Antacids containing aluminium or magnesium: may lower bilastine absorption. - Fruit juices (grapefruit, orange): can reduce oral bioavailability. - Other antihistamines: additive sedation or anticholinergic effects.